Literature DB >> 17251276

Type 2 diabetes and the risk of Parkinson's disease.

Gang Hu1, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen, Jaakko Tuomilehto.   

Abstract

OBJECTIVE: To evaluate whether type 2 diabetes at baseline is a risk factor for Parkinson's disease. RESEARCH DESIGN AND METHODS: We prospectively followed 51,552 Finnish men and women 25-74 years of age without a history of Parkinson's disease at baseline. History of diabetes and other study parameters were determined at baseline using standardized measurements. Ascertainment of the Parkinson's disease status was based on the nationwide Social Insurance Institution's drug register data. Hazard ratios of incident Parkinson's disease associated with the history of type 2 diabetes were estimated.
RESULTS: During a mean follow-up period of 18.0 years, 324 men and 309 women developed incident Parkinson's disease. Age- and study year-adjusted hazard ratios of incident Parkinson's disease among subjects with type 2 diabetes, compared with those without it, were 1.80 (95% CI 1.03-3.15) in men, 1.93 (1.05-3.53) in women, and 1.85 (1.23-2.80) in men and women combined (adjusted also for sex). Further adjustment for BMI, systolic blood pressure, total cholesterol, education, leisure-time physical activity, smoking, alcohol drinking, and coffee and tea consumption affected the results only slightly. The multivariate adjusted association between type 2 diabetes and the risk of Parkinson's disease was also confirmed in stratified subgroup analysis.
CONCLUSIONS: These data suggest that type 2 diabetes is associated with an increased risk of Parkinson's disease. Surveillance bias might account for higher rates in diabetes. The mechanism behind this association between diabetes and Parkinson's disease is not known.

Entities:  

Mesh:

Year:  2007        PMID: 17251276     DOI: 10.2337/dc06-2011

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  138 in total

Review 1.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

Review 2.  Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases.

Authors:  Shivani Ghaisas; Joshua Maher; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2015-11-26       Impact factor: 12.310

Review 3.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

4.  Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease.

Authors:  Jose A Santiago; Judith A Potashkin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

Review 5.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

6.  Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease.

Authors:  Kelly Claire Simon; Honglei Chen; Michael Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

7.  The importance of the cellular stress response in the pathogenesis and treatment of type 2 diabetes.

Authors:  Philip L Hooper; Gabor Balogh; Eric Rivas; Kylie Kavanagh; Laszlo Vigh
Journal:  Cell Stress Chaperones       Date:  2014-02-13       Impact factor: 3.667

8.  Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Honglei Chen; Thomas H Mosley; Alvaro Alonso; Xuemei Huang
Journal:  Am J Epidemiol       Date:  2009-03-18       Impact factor: 4.897

9.  Evaluation of a SNP map of 6q24-27 confirms diabetic nephropathy loci and identifies novel associations in type 2 diabetes patients with nephropathy from an African-American population.

Authors:  Tennille S Leak; Josyf C Mychaleckyj; Shelly G Smith; Keith L Keene; Candace J Gordon; Pamela J Hicks; Barry I Freedman; Donald W Bowden; Michèle M Sale
Journal:  Hum Genet       Date:  2008-06-17       Impact factor: 4.132

10.  Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism.

Authors:  Zane B Andrews; Derek Erion; Rudolph Beiler; Zhong-Wu Liu; Alfonso Abizaid; Jeffrey Zigman; John D Elsworth; Joseph M Savitt; Richard DiMarchi; Matthias Tschoep; Robert H Roth; Xiao-Bing Gao; Tamas L Horvath
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.